Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma

Gregory W. Hosier, Matthew T. Roberts

Abstract


Vemurafenib is a selective inhibitor of overactive BRAF oncogene with a substitution of lysine for glutamic acid at residue 600 (BRAFV600E), a mutation expressed in approximately 50% of all melanomas. We report a case of a patient with metastatic melanoma treated with vemurafenib, who subsequently presented with a biopsy-proven conventional renal cell carcinoma (RCC). We observed an initial complete regression of the mass while on vemurafenib. This was unexpected, given that vemurafenib is a specific inhibitor of BRAFV600E and most RCCs do not harbour this mutation.

Full Text:

PDF


DOI: http://dx.doi.org/10.5489/cuaj.3652